BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

Three-month immunity data for Moderna, NIH COVID vaccineNIH reported in The New England Journal of Medicine that all 34 Phase I subjects who received two doses of 100 ug mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) 28 days apart had...
BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...
BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology at the Genentech Inc. unit of...
BioCentury | Dec 2, 2020
Product Development

Ovid to focus on rare epilepsy program after Phase III failure for gaboxadol in Angelman syndrome

Ovid is shifting its focus to its other late-stage program, soticlestat, after gaboxadol failed in the Phase III NEPTUNE study to treat Angelman syndrome. Ovid Therapeutics Inc. (NASDAQ:OVID) fell $3.65 (55%) to $3 on Wednesday...
BioCentury | Dec 2, 2020
Finance

Canbridge broadens investor syndicate with $43M series E

The addition of $43 million in new series E cash to Canbridge’s balance sheet may better prepare it for a listing, but the company isn’t saying when or where it might go public. At the...
BioCentury | Dec 2, 2020
Distillery Therapeutics

SQSTM1, INSR identified as targets in sepsis

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Inhibiting the scaffold protein SQSTM1 or its extracellular receptor INSR could treat bacterial sepsis. Among 40 patients with bacterial sepsis, survivors had lower peripheral blood mononuclear cell mRNA levels of SQSTM1...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

DISEASE CATEGORY: Ophthalmic disease INDICATION: Ocular hypertension Penn researchers showed that NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced retinal ganglion cell death and mRNA levels of...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer; melanoma PCSK9 inhibition could treat melanoma, breast, colorectal and other cancers, and enhance the efficacy of PD-1 inhibitors. In cohorts of melanoma, liver, pancreatic, bladder, lung, kidney and...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Blueprint gains broader FDA label for Gavreto FDA approved Gavreto pralsetinib from Blueprint Medicines Corp. (NASDA:BLUE) to treat advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory thyroid cancer in patients at...
Items per page:
1 - 10 of 37104